Compare Bristol-Myers Squibb Co (BMY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Merck & Co., Inc. — how do they compare? Bristol-Myers Squibb Co trades at $62.67 (market cap $128.81B), while Merck & Co., Inc. trades at $149.19 (market cap $362.35B). The key difference: Merck & Co., Inc. is far larger — about 2.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4%). Which is the better fit depends on your goals — on Pluang, investors hold Bristol-Myers Squibb Co for 93 Days and Merck & Co., Inc. for 98 Days on average.
| BMY | MRK | |
|---|---|---|
Market Cap | $128.81B | $362.35B |
Volume | 36,831,221 | 30,469,198 |
Sector | Health | Health |
52-Week High | $68.09 | $156.43 |
52-Week Low | $42.60 | $77.60 |
Typical Hold Time | 93 Days | 98 Days |
Enterprise Value | $162.80B | $409.12B |
Dividend Yield | 4% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.06, up 0.35% on the day, with a bearish technical signal but strong fundamental metrics including a P/E of 13.89 and net income margin of 18.87%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while the stock faces headwinds from a patent cliff and competitive pressures in the pharmaceutical sector.
The outlook is mixed: analyst consensus targets $70.00 with 48% buy ratings, but technical indicators suggest near-term weakness. Key risks include debt levels and generic competition, while opportunities lie in pipeline advancements like Sotyktu's durable efficacy data. Investors should weigh solid profitability against sector-specific challenges.
Merck (MRK) trades at $146.76, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $158.12. The company reported strong Q2 2026 earnings, beating expectations, and is actively expanding its pipeline through acquisitions like Terns Pharmaceuticals. Revenue for 2025 reached $65.01B with a net income margin of 4.77%, though valuation ratios such as a P/E of 117.5 suggest high expectations.
The outlook for MRK is positive, supported by strategic M&A and consistent earnings beats, but risks include high valuation multiples and competitive pressures in the pharma sector. Investors should weigh the growth potential from recent acquisitions against the stock's premium pricing and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
